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Abstract
Background
Ex vivo heart perfusion systems, allowing continuous perfusion of the coronary vasculature,
have recently been introduced to limit ischemic time of donor hearts prior to transplantation.
Hearts are, however, perfused in an unloaded manner (via the aorta) and therefore, cardiac
contractile function cannot be reliably evaluated.
Objectives
We aim to develop a ventricular loading device that enables monitoring of myocardial func-
tion in an ex vivo perfusion system. In this initial study, was to develop a prototype for rat
experimentation.
Methods
We designed a device consisting of a ventricular balloon and a reservoir balloon, connected
through an electronic check valve, which opens and closes in coordination with changes in ven-
tricular pressure. All balloons were produced in our laboratory and their properties, particularly
pressure-volume relationships, were characterized. We developed a mock ventricle in vitro test
system to evaluate the device, which was ultimately tested in ex vivo perfused rat hearts.
Results
Balloon production was consistent and balloon properties were maintained over time and
with use on the device. Results from in vitro and ex vivo experiments show that the device
functions appropriately; hemodynamic function can be measured and compares well to
measurements made in an isolated, working (loaded) rat heart preparation.
Conclusions
Our cardiac loading device appears to reliably allow measurement of several left ventricular
hemodynamic parameters and provides the opportunity to control ventricular load.
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Introduction
Heart transplantation (HTx) remains the gold standard treatment to improve quality of life
and survival in patients with advanced heart failure. Despite acceptable results, improvement
is still possible and urgently needed. Indeed, although survival after HTx has remarkably
improved over the last 2 decades[1], the incidence and mortality from primary graft dysfunc-
tion (PGD) remains elevated[2,3] contributing to up to 30% of post-transplantation deaths.
Furthermore, insufficient supply of grafts has become critical. Increasing the number of poten-
tially available organs with marginal donors and donation after circulatory death (DCD), in
addition to conventional donation after brain death (DBD), are promising options. However,
with marginal donation and DCD, evaluation of graft suitability for transplantation takes on
an even greater importance. For example, DCD organs undergo an inevitable period of warm,
global ischemia, which requires specialized strategies to limit ischemia-reperfusion injury and
ensure adequate post-transplant functional recovery[4].
Recently, an ex vivo cardiac graft perfusion system, the Organ Care System (OCS) from
TransMedics™[5], has become available. The OCS was first developed and tested in clinical
practice for DBD HTx, showing intermediate outcomes similar to standard static storage[6],
thereby attesting to its safety. It has also been introduced for DCD HTx to protect cardiac
grafts from additional ischemia and to monitor cardiac function. The current system allows
continuous perfusion of the coronary vasculature (via the aorta) during graft storage and
transport. This however is performed in a Langendorff / unloaded mode i.e. the heart returns
to a beating state, but the left ventricle (LV) remains unloaded. In this configuration, cardiac
function cannot be fully evaluated.
In recent reports of DCD HTx, two differing approaches have been used towards graft eval-
uation. In the first, cardiac grafts are returned to the beating state while perfused on the OCS,
during which time the graft evaluated by several parameters including lactate release/ extrac-
tion [7]. The second approach involves in vivo normothermic regional perfusion (NRP)[8].
For this, the heart is reperfused in vivo with extracorporeal membrane oxygenation (ECMO)
after declaration of death. The heart is then weaned from ECMO and measurement of hemo-
dynamic function is possible via catheterization and echocardiography. Interestingly, graft
evaluations using arterial lactate profile measured on the OCS are not always concordant with
in vivo functional assessment. This discrepancy clearly demonstrates the importance of
improving methods to evaluate cardiac graft function with DCD.
Since ex vivo cardiac graft perfusion is becoming established in heart transplantation, it is
highly desirable to identify methods for a more thorough assessment of contractile function,
without requiring in vivo heart evaluation or complex, ex vivo, working mode graft perfusions.
Our ultimate objective is to develop a loading device that can be adapted to currently used
perfusion systems such as the OCS and that would allow a precise and reliable evaluation of
the cardiac graft contractile function. In the current study, we aimed to develop a miniaturized
device for rat experimentation and to verify its ability to monitor cardiac hemodynamic func-
tion using an ex vivo perfused rat heart model.
Methods
Device description
We designed a cardiac loading device (CLD) consisting of a ventricular balloon (VB, with a
volume of either 240 or 280 μL) and a reservoir balloon (RB, with a volume of 4.2 mL), con-
nected with tubing and filled with water. An electronic check valve (ECV; 2/2 NC solenoid
pinch valve series 284, ASCO Numatics, Florham Park, NJ, USA) controls the flow between
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the balloons in a binary manner, as shown in Fig 1. With this design, the water can move freely
between the balloons through the ECV when it is open, but the volumes in each section of the
device (ventricular or reservoir) remain fixed when the ECV is closed. One 3-way stopcock
and one hemostasis valve are placed on either side of the ECV to permit, respectively, volume
adjustment and insertion of micro-tip pressure catheters (Millar, Houston, USA). The pressure
catheters are used for continuous measurement of internal balloon pressures.
The CLD was designed for use with the isolated, perfused rat heart preparation. The VB is
inserted into the LV via the mitral valve, while the RB remains outside the heart. The internal
balloon pressures are used to control the ECV. When the pressure in the VB exceeds a chosen
(pre-set) ‘afterload’ value, the ECV opens. The ECV is set to close after a chosen (pre-set) delay
period. As such, ECV function corresponds with the cardiac cycle as follows: ECV opening
occurs at the time of aortic valve opening, and ECV closing occurs at the time of mitral valve
closing. The function of the device over the cardiac cycle is detailed in Fig 2. Pressures are
recorded with a PowerLab data acquisition system (ADInstruments, Spechbach, Germany)
and the ECV is controlled using the ‘Fast Response Output’ add-on of LabChart (ADInstru-
ments, Spechbach, Germany).
Fig 1. Design of cardiac loading device. (A) The cardiac loading device (CLD) consists of a ventricle balloon and a reservoir balloon connected by tubing, in which an
electronic check valve (ECV) is placed. In each section of tubing between the ECV and balloon, a hemostasis valve and a syringe port are located for insertion of
catheters and for control of device volume (pressure), respectively; (B) Photo of the CLD.
https://doi.org/10.1371/journal.pone.0195721.g001
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Balloon production
All balloons were designed and produced in our laboratory. Two LV ellipsoid Plexiglas posi-
tives for VBs were designed with volumes of 240 or 280 μL, estimated using previously
obtained data[4]. RBs were designed with a spherical shape and a larger volume of 4.2 mL, to
limit pressure in the device with the maximal volume increase of 280 μL (occurs only if VB
empties completely).
VBs were custom-made using Plexiglas positives and AlpaSil 32 Silicone A + B (Silitec AG;
Gu¨mligen, Switzerland). The silicone mixture was de-gassed by centrifugation at 4500G for 1
minute at 18˚C. The balloon positives were then immediately dipped in de-gassed silicone and
centrifuged at 44G for 5 minutes at 18˚C. Balloons were polymerized at room temperature for
24 hours, and then removed by gently sliding them off.
Because of the much larger size, RBs were manufactured using a slightly different protocol.
First, a negative mold was produced using Bluesil RTV silicone (Silitec AG; Gu¨mligen, Swit-
zerland) and a Plexiglas positive. The silicone mixture was de-gassed by centrifugation (as
above) and the positive was placed in the RTV silicone. After 24 hours of polymerization, the
RTV silicone mold was cut to remove the Plexiglas positive. The RTV silicone mold was then
used to produce positives with water-soluble wax (Freeman Sol-U-Carv wax, Freeman
Manufacturing & Supply Company, Avon, USA). To do so, the wax was melted by heating and
injected into the bottom of the mold. After 20 minutes, the solidified wax positive was gently
removed from the molds, dipped in de-gassed AlpaSil 32 Silicone mixture, and centrifuged at
Fig 2. In vitro ventricular simulator tests. In vitro ventricular simulator testing demonstrates appropriate functioning of balloon device: 1: pressure in heart chamber
increases, causing pressure in VB to exceed set afterload and opening if ECV; this is followed by VB emptying (pressure decreases) and RB filling (pressure increases) 2:
pressure in VB falls below pressure in RB, this results in refilling of VB 3: refilling of VB complete; pressure in RB falls below preload pressure; ECV closes.
https://doi.org/10.1371/journal.pone.0195721.g002
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44G for 5 minutes at 18˚C. Balloons were then polymerized for 24 hours at room temperature
and wax removed by solubilization in hot water.
Balloon characterization
All balloons were characterized by thickness, measured at room temperature (RT) at the neck
using digital electronic calipers (Fine Science Tools FST, Heidelberg, Germany), and by pres-
sure-volume (PV) relationships.
PV relationship tests were repeated at RT to determine the stability of the balloon character-
istics over time (’weekly’ tests) and with use. For this, a test system was established by connect-
ing the balloon with a pressure transducer (TruWave Disposable Pressure Transducer,
Edwards Lifesciences; Irvine, California, USA) via a 3-way stopcock. The 3-way stopcock was
also connected to a 5 mL syringe and a 250 μL Hamilton syringe for volume adjustment and
measurement. The whole system was filled with water and completely de-gassed. Pressure
within the system was continuously recorded using a PowerLab data acquisition system.
For VBs, PV tests were performed over the expected working volume range and beyond.
Briefly, the VB was filled to the maximum filling volume (i.e. 240/280 μL), and then volume in
the balloon was increased by 50 μL (increments of 10 μL) using a Hamilton syringe and then
returned to its initial value. The volume was then decreased, with increments of 10 μL, by 240/
280 μL (maximum filling volume). The maximal working volume was defined as the maxi-
mum volume at which the balloon did not exert any pressure.
The procedure was slightly different for RBs. After setting the initial volume to a pressure of
11.5 mmHg (standard preload pressure), we first decreased the volume in the balloon by
50 μL, returned to initial volume, and then increased the volume by 250 μL (always with incre-
ments of 10 μL). The elastic resistance of the reservoir balloons, also known as the elastance,
was then determined by calculating the slope of the PV curve by linear regression[9], as fol-
lows:
slope ¼
dP
dV
¼ elastance
For VBs and RBs, PV relation measurements were repeatedly performed (according to the
procedure described above) once a week over 24 weeks to detect possible changes in balloon
properties over time.
In vitro ventricle simulator tests
We have also developed an in vitro test system to evaluate the function of the CLD. It consists
of a pressure generator for the ventricle simulator, connected to a heart chamber. A rotating
motor, connected to a power supply, moves a base plate on which the plunger(s) of syringe(s)
is (are) fixed. The pressure developed and heart rate can be varied depending on the number
of syringes used and the rate at which the base plate moves (maximum of 230 bpm, technical
limit), respectively. With this system, we tested the CLD for 1h, at a heart rate of 230 bpm and
a developed pressure of 100 mmHg.
Over use tests
Tests were performed to determine whether the balloon characteristics change with use on the
in vitro ventricle simulator. First, we measured balloon PV relationships and then used them
in the simulator for 1 hour as described above. Thereafter, the PV relationships were measured
once again.
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Isolated perfused rat heart tests
Ethics statement. All experimental procedures were performed in compliance with the
European Convention for Animal Care and approved by the Swiss animal welfare authorities
and state veterinary office (Ethics Committee for Animal Experimentation, Bern, Switzerland;
Authorization of Animal Experimentation BE88/16). Surgery was performed under anesthesia
and all efforts were made to minimize animal suffering.
Isolated heart preparation. Adult male Wistar rats (n = 6; 387 ± 17 g; Janvier Labs, Le
Genest-Saint-Isle, France), housed under standard conditions with unlimited access to food
(standard laboratory diet ad libitum) and water, were anesthetized with an intraperitoneal
injection of 100 mg/kg ketamine (Narketan™, Vetoquinol AG, Bern, Switzerland) and 10 mg/
kg xylazine (Xylapan™, Vetoquinol AG, Bern, Switzerland).
After anesthesia and as soon as the pedal reflex had disappeared, hearts were excised and
immediately placed in ice-cold PBS. Hearts were then perfused in an unloaded manner, via the
cannulated aorta, with a modified Krebs-Henseleit bicarbonate (KHB) buffer containing: 118
mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4  7H2O, 1.25 mM CaCl2  7H2O, 25
mM NaHCO3 and 11 mM glucose[4,10,11], at a constant pressure of 60 mmHg[4,10,11].
Once the left atrium was cannulated, hearts were switched to working (loaded) mode perfusion
and a micro-tip pressure catheter (Millar, Houston, USA) was inserted into the LV. The preload was
maintained at 11.5 mmHg, and the afterload was kept at 60 mmHg for 20 min and then increased
to 80 mmHg for another 20 min. During this time, continuous catheter-based measurements were
recorded in the working (loaded) mode for comparison with values obtained using the CLD.
For testing the CLD, hearts were returned to the unloaded mode. The deflated VB was
inserted into the LV via the mitral valve. Thereafter, the VB was filled with ddH2O using a 250 μL
Hamilton syringe, and the CLD was started at a preload of 11.5 mmHg and an afterload of 60
mmHg. The afterload was then increased after 20 min to 80 mmHg for an additional 20 min.
Data analysis
For PV relationship tests, pressure measurements were first normalized to the initial pressure
to limit technical variation.
Unless stated otherwise, values are reported as mean ± SD. Data analysis was performed
with GraphPad Prism (version 7.0, GraphPad Software Inc., La Jolla, CA, USA). Differences in
the balloon characteristics among batches were evaluated non-parametrically using Mann-
Whitney tests. Pairwise comparisons were performed non-parametrically to compare the bal-
loon characteristics over time and over use using Wilcoxon matched-pairs signed rank tests.
All p values were two sided, adjusted for multiple comparisons (modified sequential rejec-
tive Bonferroni procedure[12]) and reported after correction. Corrected p values were consid-
ered statistically significant if p<0.05.
Results
A total of 96 balloons were produced (33 RBs and 63 VBs) in thirteen batches (groups of bal-
loons produced together), permitting the evaluation of both production consistency and evalu-
ate balloon properties. We were able to reach a production yield of up to 100% and 60% for the
VB and RB, respectively.
Balloon characterization
Baseline measurements. All balloons were tested after fabrication. No significant differ-
ence in VB thickness or PV relationship was observed between batches (Fig 3A and 3B). We
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also measured maximal working volumes of 200 μL and 230 μL for the 240 μL and 280 μL VB
molds, respectively, as shown in Fig 3C and 3D. When approaching withdrawal of the maxi-
mum working volume, pressure changes were observed and variability among balloons dra-
matically increased.
Balloon thickness was also similar between batches of RBs (Fig 4A). However, small differ-
ences in the PV relationship and elastance (coefficient of determination R2 >0.997) were
observed for these balloons (Fig 4B and 4C). A negative correlation (p<0.05) between the ela-
stance of the RB and the ‘age’ of the silicone (i.e. time between the opening of the silicone bot-
tles and the balloon production) was measured, as shown in Fig 4D. For simplicity, elastance,
not PV relationships, is reported for reservoir balloon evaluations.
Weekly measurements. No change in PV relationships or maximal working volume of
the VB (batches 2 & 4) was measured over time for up to 24 weeks after fabrication (Fig 5A
and 5B). Similarly, no change in elastance of the RB (batches 1, 3 & 4) was observed over time
for up to 24 weeks after production (Fig 5C–5E).
In vitro ventricle simulator tests. An example of an in vitro test is presented in Fig 2. The
pressure in the VB increases according to the pressure generated in the ventricle simulator.
When the VB pressure exceeds the set afterload (e.g. 80 mmHg in an example of curves pre-
sented in Fig 2), the ECV opens (Fig 2, Line 1). The VB pressure briefly overshoots the after-
load pressure, then it falls (VB empties), and the RB expands (pressure increases). When VB
pressure falls below RB pressure, refilling of the VB starts (Fig 2, Line 2). Finally, when VB
refilling is complete, the pressure in the RB falls below the preload pressure (e.g. 11.5 mmHg)
and the ECV closes (Fig 2, Line 3). This completes one heart cycle.
Fig 3. Baseline characteristics of ventricular balloons. (A) Thickness of ventricular balloons (VB); (B) PV relationship of VBs according to batch; (C)
pressure for all 240 μL VBs at volumes of -100, -190, -200, -210, -220 μL; (D) pressure for all 280 μL VBs at volumes of -100, -230, -240, -250 μL. Data are
normalized to initial pressure (volume = 0) and expressed as mean ± SD. n = 2–9 per group.
https://doi.org/10.1371/journal.pone.0195721.g003
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Using the ventricle simulator, we have determined the optimal valve delay time (t) for sev-
eral heart rates (x; 125–230 bpm), fitting it to a polynomial curve (R2 = 0.983):
t ¼ fðxÞ ¼   1:574 10  8  x3 þ 1:056 10  5  x2   3:028 10  3  xþ 0:5155
Over use measurements. We did not note any difference in PV relationship, nor in maxi-
mal working volume of VBs (batches 1 & 3) after use on the CLD for one hour (Fig 6A and
6B). Similarly, no difference in elastance of RBs (batches 2 & 5) was observed (Fig 6C).
Isolated perfused rat heart tests
Our CLD allows the assessment of heart rate, developed pressure, dP/dtmax and dP/dtmin in
isolated beating rat hearts. Overall, no significant difference (p>0.05) was observed when com-
pared to measurements obtained with the working (loaded) heart system at 60 mmHg, except
for dP/dtmax at 20 minutes as shown in Fig 7. However, the CLD tended to underestimate the
values of developed pressure (correction factor: 0.88±0.23), dP/dtmax (0.63±0.18), dP/dtmin
(0.90±0.21), and overestimate cardiac output (1.13±0.38).
Discussion
We present initial results with a cardiac loading device conceptualized and developed for the
functional evaluation of isolated hearts. This device permits left ventricle loading and ejection,
and therefore, measurement of cardiac pump function in ex vivo hearts perfused in the
Fig 4. Baseline characteristics of reservoir balloons. (A) Thickness of reservoir balloons (RB); (B) PV relationship of RB according to batch; (C)
elastance of RB; (D) negative correlation between the elastance of the RB and silicone ‘age’. Data are normalized to initial pressure (volume = 0) and
expressed as mean ± SD.  p<0.05. n = 3–6 per group.
https://doi.org/10.1371/journal.pone.0195721.g004
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unloaded, Langendorff mode. We demonstrate that balloons for the device can be manufac-
tured consistently and that their properties are retained over time and with use. Furthermore,
as proof of concept, we successfully measured several hemodynamic parameters with our CLD
in the isolated, perfused, working (loaded) rat heart. This type of device could be of use in both
laboratory experimentation and clinical applications.
The CLD that we describe was sized to fit rat hearts, and is designed for research applica-
tions in which characterization of cardiac function is critical. Several research protocols use
Fig 5. Pressure-volume (PV) relationship for ventricular and reservoir balloons: Weekly tests. Weekly measurements of PV relationships for VB batches 2 (A)
and 4 (B); Reservoir balloon elastance for batches 1 (C), 3 (D) and 4 (E). Week 0 and 1 correspond to testing within one week of production and one week after
production, respectively. Data are normalized to initial pressure (volume = 0) and expressed as mean ± SD. n = 3–7 per group.
https://doi.org/10.1371/journal.pone.0195721.g005
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isolated, perfused hearts in the Langendorff or unloaded mode for cardiac evaluation. This
approach, although relatively simple and highly reproducible, has a very limited interest for
the assessment of the contractile function, as the LV remains unloaded. Isovolumetric, intra-
ventricular balloons are sometimes used with these preparations to monitor LV contractile
function. This assessment of LV function is, however, limited to the pressure generated by the
LV against a fixed resistance, which is not representative of a clinical scenario. In an ex vivo
perfused heart, the best current approach to evaluate LV contractile function is the working or
loaded configuration, in which physiological flow of perfusate or blood through the heart
chambers is respected. The establishment of such a system, however, requires greater technical
expertise and is more costly. Our cardiac loading device has the major advantage that it can be
simply added to a regular Langendorff (unloaded) heart perfusion system, thereby offering an
alternative that enables continuous monitoring of contractile function of the left ventricle dur-
ing the entire ventricular “loading” and “unloading” phases, without the demands of a tradi-
tional working-heart system.
Our results from experiments with isolated, perfused rat hearts indicate that the device is
effective for ventricular loading and evaluation of hemodynamic parameters, such as heart
rate, developed pressure, dP/dtmax and dP/dtmin. Our findings also indicate that the estimation
of the cardiac output is possible. Heart rate measurements look almost identical between those
obtained with the CLD and those obtained with the classically loaded heart preparation, as
would be expected. However, CLD measurements of developed pressure, dP/dtmax and dP/
dtmin tend to be slightly lower (higher for cardiac output) than those in the classical heart prep-
aration. Importantly, this tendency for lower values is not necessarily problematic; CLD values
Fig 6. Pressure-volume (PV) relationships for ventricular and reservoir balloons: With use tests. PV relationships (VB) for batches 1 (A) and 3 (B) and
calculated elastance (RB) for batches 2, 5 and 6 (C) measured before and after one-hour use on ventricular simulator. Data are normalized to initial pressure
(volume = 0) and expressed as mean ± SD. n = 3–6 per group.
https://doi.org/10.1371/journal.pone.0195721.g006
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only need to reflect true heart function. Values measured with the CLD can be adjusted using
correction factors for more precise results.
Our cardiac loading device could be of interest for both preclinical and clinical applications.
In addition to hemodynamic assessment in isolated, perfused rat hearts, the principle could be
applied in larger species, such as rabbits, or pigs. With an adapted design, it could be implanted
in an experimental model of heterotopic transplantation[13], thereby permitting characteriza-
tion of ventricular load (preload and afterload) on the reverse remodeling process[14]. In clini-
cal practice, the CLD principle could be used with an ex vivo perfusion apparatus such as the
OCS, for the evaluation of graft function before transplantation. This would be of particular
Fig 7. Results of isolated rat hearts. Heart rate (A), developed pressure (B), dP/dtmax (C), dP/dtmin (D), cardiac output (E) with the isolated working rat heart
system (system) and our cardiac loading device (CLD), for afterloads of 60 and 80 mmHg. (F) Picture of CLD in an isolated rat heart. Data are expressed as
mean ± SD.  p<0.05, n = 3–6 per group.
https://doi.org/10.1371/journal.pone.0195721.g007
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interest for DCD heart transplantation since current graft evaluation possibilities remains
rudimentary, and may limit the expansion of DCD use in heart transplantation.
We established a ventricle simulator to test our device in vitro prior to performing ex vivo
tests. This in vitro system was very valuable for developing our CLD and determining the
appropriate estimate for the valve delay time, which is dependent on heart rate. Our results
from these in vitro tests show that the CLD functions appropriately for at least one hour at a
heart rate of 230 bpm and a developed pressure of 100 mmHg.
In order to develop our CLD, it was necessary to establish fabrication techniques for the
consistent and reliable production of both VBs and RBs. Importantly, we did not measure any
significant difference in PV relationships or maximal working volumes (p>0.05) for VBs
among batches. Our results also indicate that the PV relationship for RBs is almost linear, ren-
dering the calculation of elastance by linear regression accurate (R2> 0.997). However, we
measured a significant decrease in elastance of the RB between batches (p<0.05), when the
time between the opening of the silicone bottles and the production of the balloons was longer,
as demonstrated by the negative correlation (p<0.05) between the elastance of the reservoir
balloons and the ’age’ of the silicone. In order to avoid these differences, it is necessary to con-
trol and monitor the time between the opening of the silicone bottle and its use. Thus, apart
from silicone-age-related differences in elastance for the RB, balloon production is very consis-
tent. Our results from ‘weekly’ and ‘over use’ tests show that the PV properties of both VBs
and RBs are stable, with no detectable changes for up to 24 weeks after production, respec-
tively, and no changes after 1 hour use with the CLD (p>0.05).
We have developed a simple, reliable method to manufacture VBs that are very thin, flexible,
compliant and with properties that remain constant, and which could be used for other applica-
tions, such as isovolumetric, Langendorff heart perfusions. Indeed, in these experiments, a
fluid-filled intraventricular balloon, connected to a pressure transducer and inserted into the
LV via the mitral valve, is used to measure contractile function (i.e. heart rate, ventricular pres-
sures). Many investigators performing Langendorff heart preparations use standard latex bal-
loons[15–18]; however, these balloons are neither very flexible, nor compliant. Furthermore,
latex is cytotoxic, which would limit its adequacy for long-term experimental use. Therefore,
investigators often make their own balloons from cling film/plastic wrap[19–21]. However,
properties of latex or cling film change over time and with use; therefore, balloons must be
changed quite often[22]. Although other methods to produce silicone balloons exist[23], ours is
very reproducible, providing balloons with similar volume and shape among batches.
In summary, we have developed a simple CLD and demonstrated that this approach can be
used to simulate ventricular loading and monitor hemodynamic function during ex vivo perfu-
sion, such as occurs during organ transplantation.
Limitations
The device we have presented here has been developed for application in rat experimentation
and this study should be considered as a proof of concept. Further development and adaptations
are required for use in bigger animal species, such as pigs, and before testing in human hearts.
Outlook
The continuous need to increase cardiac graft availability has led to the expansion of the donor
pool, with marginal DBD and DCD and the introduction of ex vivo graft perfusion technolo-
gies in clinical practice. Now more than ever, there is a need to improve DBD and DCD car-
diac graft evaluation, and ex vivo graft perfusion permits the development of many potential
assessment parameters, including contractile function. However, unloaded perfusions are of
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limited value and typical working model systems are technically complex in practice. Thus,
our CLD could offer a solution for improved assessment of cardiac function prior to
transplantation.
Furthermore, many laboratories worldwide are working with ex vivo, perfused heart models
in a Langendorff (unloaded) mode. Therefore, our device could help to assess cardiac hemody-
namic function more accurately. In a next generation, one could also add different physiologi-
cal and chemical stretchable sensors on the silicone of the VB to improve the methods to
evaluate cardiac graft function, which might find clinical applications in a near future.
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